#Mortality, readmission low with COVID-19 discharge on home oxygen

“#Mortality, readmission low with COVID-19 discharge on home oxygen”

(HealthDay)—For patients with COVID-19 pneumonia, rates of mortality and 30-day readmission are low with discharge on home oxygen, according to a study published online April 1 in JAMA Network Open.

Josh Banerjee, M.D., M.P.H., from the Los Angeles County + University of Southern California Medical Center, and colleagues conducted a retrospective cohort study involving 621 adult patients with COVID-19 pneumonia who were discharged from two large urban public hospitals from March 20 to Aug. 19, 2020. Patients receiving at least 3 L/min of oxygen who were stable without other indications for inpatient care were discharged with home oxygen equipment, educational resources, and nursing telephone follow-up within 12 to 18 hours of discharge.

Of the patients, 24 and 76 percent were discharged from the emergency department and inpatient encounters, respectively. The researchers found that within a median follow-up time of 26 days, the all-cause mortality rate was 1.3 percent, and the 30-day readmission rate was 8.5 percent. In the ambulatory setting, no deaths occurred.

“This expected practice may be considered part of a strategy to ensure right care, right place, and right time for patients with COVID-19 pneumonia, and to preserve acute care access during the pandemic,” the authors write.

Follow the latest news on the coronavirus (COVID-19) outbreak

More information:
Abstract/Full Text

Citation:
Mortality, readmission low with COVID-19 discharge on home oxygen (2021, April 2)
retrieved 3 April 2021
from https://medicalxpress.com/news/2021-04-mortality-readmission-covid-discharge-home.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

If you liked the article, do not forget to share it with your friends. Follow us on Google News too, click on the star and choose us from your favorites.